Toll-like receptors and the genetics of innate immunity

Current Opinion in Allergy and Clinical Immunology

Volumn 3, Issue 6, 2003, Pages 523-529

  Cook, Donald N ^a   Hollingsworth II, John W ^a   Schwartz, David A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Asp299Gly; Genetics; MyD88; Signaling; Tirap; Toll like receptors

Indexed keywords

BACTERIAL TOXIN; BACTERIUM LIPOPOLYSACCHARIDE; DNA; DOUBLE STRANDED RNA; I KAPPA B; INTERLEUKIN 18; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MYELOID DIFFERENTIATION FACTOR 88; RNA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; CELL SURFACE RECEPTOR; MEMBRANE PROTEIN;

ALLELE; ASTHMA; ATHEROSCLEROSIS; CELL ACTIVATION; CORRELATION ANALYSIS; DENDRITIC CELL; DNA POLYMORPHISM; GENE CONTROL; GENE TARGETING; GENETIC ANALYSIS; GENOTYPE PHENOTYPE CORRELATION; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; MOLECULAR CLONING; MOLECULAR GENETICS; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; ANIMAL; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; PHYSIOLOGY;

ANIMALS; HUMANS; IMMUNITY, NATURAL; LIGANDS; MEMBRANE GLYCOPROTEINS; POLYMORPHISM, GENETIC; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 2442555557     PISSN: 15284050     EISSN: None     Source Type: Journal    
DOI: 10.1097/00130832-200312000-00016     Document Type: Review

References (86)

1. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in TIr4 gene. Science 1998; 282:2085-2088.
2. Hoshino K, Takeuchi O, Kawai T, et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999; 162:3749-3752.
3. Barton GM, Medzhitov R. Toll-like receptors and their ligands. Curr Top Microbiol Immunol 2002; 270:81-92.
4. Bausinger H, Lipsker D, Ziylan U, et al. Endotoxin-free heat-shock protein 70 fails to induce APC activation. Eur J Immunol 2002; 32:3708-3713. This is an important paper demonstrating that small concentrations of lipopolysaccharide can account for the activity of preparations that induce TLR signaling activity.
5. Bulut Y, Faure E, Thomas L, et al. Chlamydial heat shock protein 60 activates macrophages and endothelial cells through Toll-like receptor 4 and MD2 in a MyD88-dependent pathway. J Immunol 2002; 168:1435-1440.
6. Sasu S, LaVerda D, Qureshi N, et al. Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ Res 2001; 89:244-250.
7. Malley R, Henneke P, Morse SC, et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci U S A 2003; 100:1966-1971.
8. Rassa JC, Meyers JL, Zhang Y, et al. Murine retroviruses activate B cells via interaction with toll-like receptor 4. Proc Natl Acad Sci U S A 2002; 99:2281-2286.
9. Okamura Y, Watari M, Jerud ES, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001; 276:10229-10233.
10. Termeer C, Benedix F, Sleeman J, et al. Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002; 195:99-111.
11. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 2002; 168:5233-5239.
12. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 2001; 167:2887-2894.
13. Tada H, Nemoto E, Shimauchi H, et al. Saccharomyces cerevisiae- and Candida albicans-derived mannan induced production of tumor necrosis factor alpha by human monocytes in a CD14- and Toll-like receptor 4-dependent manner. Microbiol Immunol 2002; 46:503-512.
14. Mambula SS, Sau K, Henneke P, et al. Toll-like receptor (TLR) signaling in response to Aspergillus fumigatus. J Biol Chem 2002; 277:39320-39326.
15. Echchannaoui H, Frei K, Schnell C, et al. Toll-like receptor 2-deficient mice are highly susceptible to Streptococcus pneumoniae meningitis because of reduced bacterial clearing and enhanced inflammation. J Infect Dis 2002; 186:798-806.
16. Koedel U, Angele B, Rupprecht T, et al. Toll-like receptor 2 participates in mediation of immune response in experimental pneumococcal meningitis. J Immunol 2003; 170:438-444.
17. Massari P, Henneke P, Ho Y, et al. Cutting edge: immune stimulation by neisserial porins is toll-like receptor 2 and MyD88 dependent. J Immunol 2002; 168:1533-1537.
18. Girard R, Pedron T, Uematsu S, et al. Lipopolysaccharides from Legionella and Rhizobium stimulate mouse bone marrow granulocytes via Toll-like receptor 2. J Cell Sci 2003; 116 (Pt 2):293-302.
19. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413:732-738.
20. Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 410:1099-1103.
21. Gewirtz AT, Navas TA, Lyons S, et al. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol 2001; 167:1882-1885.
22. Takeuchi O, Kawai T, Muhlradt PF, et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 2001; 13:933-940.
23. Ozinsky A, Underhill DM, Fontenot JD, et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci U S A 2000; 97:13766-13771.
24. Mitcham JL, Parnet P, Bonnert TP, et al. T1/ST2 signaling establishes it as a member of an expanding interleukin-1 receptor family. J Biol Chem 1996; 271:5777-5783.
25. Huang Q, Liu D, Majewski P, et al. The plasticity of dendritic cell responses to pathogens and their components. Science 2001; 294:870-875.
26. Kawai T, Adachi O, Ogawa T, et al. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999; 11:115-122.
27. Horng T, Barton GM, Flavell RA, Medzhitov R. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 2002; 420:329-333. This is another paper by an independent group of researchers showing that Mal (an alternative name for TIRAP) can be used as an adaptor molecule by TLR4.
28. Yamamoto M, Sato S, Hemmi H, et al. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 2002; 420:324-329. This important paper describes the generation and characterization of TIRAP-deficient mice. The authors suggest that TIRAP might participate in the MyD88-dependent pathway, rather than the MyD88-independent pathway.
29. Oshiumi H, Matsumoto M, Funami K, et al. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat Immunol 2003; 4:161-167. This is a very important paper identifying TICAM-1, the third known adaptor protein functioning with Toll/IL-1 receptors.
30. Horng T, Barton GM, Medzhitov R. TIRAP: an adapter molecule in the Toll signaling pathway. Nat Immunol 2001; 2:835-841.
31. Fitzgerald KA, Palsson-McDermott EM, Bowie AG, et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 2001; 413:78-83.
32. Adachi O, Kawai T, Takeda K, et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998; 9:143-150.
33. Yamamoto M, Sato S, Mori K, et al. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol 2002; 169:6668-6672. This paper independently shows that TRIF (also known as TICAM-1) is involved in the TLR3-mediated signaling pathway leading to interferon gene activation.
34. Hirschfeld M, Weis JJ, Toshchakov V, et al. Signaling by toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages. Infect Immun 2001; 69:1477-1482.
35. Toshchakov V, Jones BW, Perera PY, et al. TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. Nat Immunol 2002; 3:392-398.
36. O'Neill LA, Fitzgerald KA, Bowie AG. The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol 2003; 24:286-289. This is a very interesting paper showing that one of the IRAK family members, IRAK-M, actually negatively regulates signaling responses through the IRAK pathway. This finding is important, in part because ir it suggests that it might be possible to regulate the magnitude of inflammatory responses through IRAK-M activity.
37. Kobayashi K, Hernandez LD, Galan JE, et al. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002; 110:191-202. This paper identifies a regulatory mechanism for a member of the SOCS family.
38. Nakagawa R, Naka T, Tsutsui H, et al. SOCS-1 participates in negative regulation of LPS responses. Immunity 2002; 17:677-687. This paper identifies a regulatory mechanism for a member of the SOCS family.
39. Kinjyo I, Hanada T, Inagaki-Ohara K, et al. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity 2002; 17:583-591.
40. Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002; 168:554-561. This paper demonstrates various levels of TLR expression in different cell types.
41. Kalis C, Kanzler B, Lembo A, et al. Toll-like receptor 4 expression levels determine the degree of LPS-susceptibility in mice. Eur J Immunol 2003; 33:798-805. This paper is important because it demonstrates that levels of TLR4 influence the magnitude of the response to lipopolysaccharide in transgenic mice. This finding suggests that modulation of endogenous TLR4 might be one means of regulating the lipopolysaccharide response.
42. Bihl F, Salez L, Beaubier M, et al. Overexpression of toll-like receptor 4 amplifies the host response to lipopolysaccharide and provides a survival advantage in transgenic mice. J Immunol 2003; 170:6141-6150.
43. Vink A, Schoneveld AH, van der Meer JJ, et al. In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation 2002; 106:1985-1990.
44. Mori Y, Yoshimura A, Ukai T, et al. Immunohistochemical localization of Toll-like receptors 2 and 4 in gingival tissue from patients with periodontitis. Oral Microbiol Immunol 2003; 18:54-58.
45. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000; 68:7010-7017.
46. Matsuguchi T, Musikacharoen T, Ogawa T, Yoshikai Y. Gene expressions of Toll-like receptor 2, but not Toll-like receptor 4, is induced by LPS and inflammatory cytokines in mouse macrophages. J Immunol 2000; 165:5767-5772.
47. Lin Y, Lee H, Berg AH, et al. The lipopolysaccharide-activated toll-like receptor (TLR)-4 induces synthesis of the closely related receptor TLR-2 in adipocytes. J Biol Chem 2000; 275:24255-24263.
48. Medvedev AE, Kopydlowski KM, Vogel SN. Inhibition of lipopolysaccharide- induced signal transduction in endotoxin-tolerized mouse macrophages: dysregulation of cytokine, chemokine, and toll-like receptor 2 and 4 gene expression. J Immunol 2000; 164:5564-5574.
49. Wang T, Lafuse WP, Zwilling BS. Regulation of toll-like receptor 2 expression by macrophages following Mycobacterium avium infection. J Immunol 2000; 165:6308-6313.
50. Faure E, Thomas L, Xu H, et al. Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. J Immunol 2001; 166:2018-2024.
51. Yang Q, Zhu P, Wang Z, Jiang J. Lipopolysaccharide upregulates the expression of Toll-like receptor 4 in human vascular endothelial cells. Chin Med J (Engl) 2002; 115:286-289.
52. An H, Yu Y, Zhang M, et al. Involvement of ERK, p38 and NF-kappaB signal transduction in regulation of TLR2, TLR4 and TLR9 gene expression induced by lipopolysaccharide in mouse dendritic cells. Immunology 2002; 106:38-45.
53. Bosisio D, Polentarutti N, Sironi M, et al. Stimulation of toll-like receptor 4 expression in human mononuclear phagocytes by interferon-gamma: a molecular basis for priming and synergism with bacterial lipopolysaccharide. Blood 2002; 99:3427-3431.
54. Suzuki M, Hisamatsu T, Podolsky DK. Gamma interferon augments the intracellular pathway for lipopolysaccharide (LPS) recognition in human intestinal epithelial cells through coordinated up-regulation of LPS uptake and expression of the intracellular Toll-like receptor 4-MD-2 complex. Infect Immun 2003; 71:3503-3511.
55. + fibroblasts primed with gamma interferon increase production of interleukin-8 in response to lipopolysaccharide through up-regulation of membrane CD14 and MyD88 mRNA expression. Infect Immun 2002; 70:1272-1278.
56. Mita Y, Dobashi K, Endou K, et al. Toll-like receptor 4 surface expression on human monocytes and B cells is modulated by IL-2 and IL-4. Immunol Lett 2002; 81:71-75.
57. Kurt-Jones EA, Mandell L, Whitney C, et al. Role of toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF enhances TLR2 expression and TLR2-mediated interleukin 8 responses in neutrophils. Blood 2002; 100:1860-1868.
58. Roger T, David J, Glauser MP, Calandra T. MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 2001; 414:920-924.
59. Kaisho T, Takeuchi O, Kawai T, et al. Endotoxin-induced maturation of MyD88-deficient dendritic cells. J Immunol 2001; 166:5688-5694.
60. Schnare M, Barton GM, Holt AC, et al. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001; 2:947-950.
61. h2 cell differentiation. Int Immunol 2002; 14:695-700.
62. + T cell-mediated suppression by dendritic cells. Science 2003; 299:1033-1036. This is an important paper that illustrates a function for TLR in adaptive immunity. Signaling through TLR4 not only upregulates co-stimulatory molecules, but also blocks suppression of immune responses by T regulatory cells.
63. Szabo SJ, Kim ST, Costa GL, et al. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000; 100:655-669.
64. Liu N, Ohnishi N, Ni L, et al. CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells. Nat Immunol 2003; 4:687-693. This is an interesting and important paper that identifies a mechanism for TLR9-mediated skewing of immune responses towards T helper 1 cells. The authors demonstrate that TLR9 signaling increases transcription of the T helper 1-associated transcription factor, T-bet.
65. Eisenbarth SC, Piggott DA, Huleatt JW, et al. Lipopolysaccharide- enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med 2002; 196:1645-1651.
66. Boonstra A, Asselin-Paturel C, Gilliet M, et al. Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential toll-like receptor ligation. J Exp Med 2003; 197:101-109.
67. Lorenz E, Jones M, Wohlford-Lenane C, et al. Genes other than TLR4 are involved in the response to inhaled LPS. Am J Physiol Lung Cell Mol Physiol 2001; 281:L1106-L1114.
68. Kline JN, Cowden JD, Hunninghake GW, et al. Variable airway responsiveness to inhaled lipopolysaccharide. Am J Respir Crit Care Med 1999; 160:297-303.
69. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25:187-191.
70. Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 2002; 162:1028-1032.
71. Agnese DM, Calvano JE, Hahm SJ, et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002; 186:1522-1525.
72. Child NJ, Yang IA, Pulletz MC, et al. Polymorphisms in Toll-like receptor 4 and the systemic inflammatory response syndrome. Biochem Soc Trans 2003; 31 (Pt 3):652-653.
73. Lorenz E, Hallman M, Marttila R, et al. Association between the Asp299Gly polymorphisms in the Toll-like receptor 4 and premature births in the Finnish population. Pediatr Res 2002; 52:373-376.
74. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347:185-192. This is an interesting paper documenting the association between human TLR4 polymorphisms and the development of atherosclerosis. The authors find that a polymorphism associated with a reduced response to lipopolysaccharide is protective in vascular disease.
75. Boekholdt SM, Agema WR, Peters RJ, et al. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 2003; 107:2416-2421.
76. Palmer SM, Burch LH, Davis RD, et al. The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med 2003; May 28 (Epub ahead of print).
77. Reindl M, Lutterotti A, Ingram J, et al. Mutations in the gene for toll-like receptor 4 and multiple sclerosis. Tissue Antigens 2003; 61:85-88.
78. Lorenz E, Schwartz DA, Martin PJ, et al. Association of TLR4 mutations and the risk for acute GVHD after HLA-matched-sibling hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7:384-387.
79. Raby BA, Klimecki WT, Laprise C, et al. Polymorphisms in toll-like receptor 4 are not associated with asthma or atopy-related phenotypes. Am J Respir Crit Care Med 2002; 166:1449-1456.
80. Read RC, Pullin J, Gregory S, et al. A functional polymorphism of toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease. J Infect Dis 2001; 184:640-642.
81. Smirnova I, Mann N, Dols A, et al. Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility. Proc Natl Acad Sci U S A 2003; 100:6075-6080.
82. Lorenz E, Mira JP, Cornish KL, et al. A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 2000; 68:6398-6401.
83. Kang TJ, Chae GT. Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. FEMS Immunol Med Microbiol 2001; 31:53-58.
84. Kang TJ, Lee SB, Chae GT. A polymorphism in the toll-like receptor 2 is associated with IL-12 production from monocyte in lepromatous leprosy. Cytokine 2002; 20:56-62.
85. Hudson LD, Milberg JA, Anardi D, Maunder RJ. Clinical risks for development of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995; 151(2 Pt 1):293-301.
86. Veeze HJ, Halley DJ, Bijman J, et al. Determinants of mild clinical symptoms in cystic fibrosis patients. Residual chloride secretion measured in rectal biopsies in relation to the genotype. J Clin Invest 1994; 93:461-466.